Advanced search
Publication Cover
Clinical Lipidology Volume 4, 2009 - Issue 5
Submit an article Journal homepage
341
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Farnesoid X receptor as a therapeutic target for dyslipidemia

Mark EvansCorrespondence[email protected]
&
Stephen Gardell
Pages 587-594 | Published online: 18 Jan 2017

  • Superko HR, King S: Is lowering low-density lipoprotein an effective strategy to reduce cardiac risk? Lipid management to reduce cardiovascular risk – a new strategy Is required. Circulation 117, 560–568 (2008).
  • Discussion of the recent debate over the relative importance of LDL-C lowering for further reduction of cardiovascualr disease in humans.
  • LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).
  • Davidson MH, Maki KC, Pearson TA et al.: Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96, 556–563 (2005).
  • Bansal S, Buring JE, Rifai N et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298, 309–316 (2008).
  • Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298, 299–308 (2008).
  • Provides recent evidence for the importance of plasma triglyceride (TG) levels in the development of cardiovascular disease.
  • Bell GD, Lewis B, Petrie A, Dowling RH: Serum lipids in cholelithiasis: effect of chenodeoxycholic acid therapy. Br. Med. J. 3, 520–522 (1973).
  • Bateson MC, Maclean D, Evans JR, Bouchier AD: Chenodeoxycholic acid therapy for hypertriglyceridemia. Br. J. Clin. Pharmac. 5, 249–254 (1978).
  • Insull W: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South. Med. J. 99, 257–273 (2006).
  • Review of the knowledge gained from the use of bile acid resins in humans.
  • Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results. I Reduction in Incidence of Coronary Heart Disease. JAMA 251, 351–364 (1984).
  • Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251, 365–374 (1984).
  • Schwarz M, Russell DW, Dietschy JM, Turley SD: Marked reduction in bile acid synthesis in cholesterol 7a-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J. Lipid Res. 39, 1833–1843 (1998).
  • Kesäniemi YA, Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur. J. Clin. Invest. 17, 391–395 (1987).
  • van Himbergen TM, Matthan NR, Resteghini NA et al.: Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J. Lipid Res. 50, 730–739 (2009).
  • Gylling H, Vanhanen H, Miettinen TA: Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination. Eur. J. Clin. Invest. 37, 111–115 (1989).
  • Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including human. J. Lipid Res. 34, 1637–1659 (1993).
  • Nilsson LM, Abrahamsson A, Sahlin S et al.: Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem. Biophys. Res. Commun. 357, 707–711 (2007).
  • Important human data addressing the effect of the bile acid pool size on gene expression.
  • Abrahamsson A, Gustafsson U, Ellis E et al.: Feedback regulation of bile acid synthesis in human liver: importance of HNF-4a for regulation of CYP7A1. Biochem. Biophys. Res. Commun. 330, 395–399 (2005).
  • Berkenstam A, Kristensen J, Mellstrom K et al.: The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl Acad. Sci. USA 105, 663–667 (2008).
  • Pullinger CR, Eng C, Salen G et al.: Human cholesterol 7a-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109–117 (2002).
  • Spady D, Cuthbert JA, Willard MN, Meidell RS: Adenovirus-mediated transfer of a gene encoding cholesterol 7a-hydroxylase into hamsters increases hepatic enzyme activity and reduces plasma total and low density lipoprotein cholesterol. J. Clin. Invest. 96, 700–709 (1998).
  • Spady D, Cuthbert JA, Willard MN, Meidell RS: Overexpression of cholesterol 7a-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene. J. Biol. Chem. 273, 126–132 (1998).
  • Miyake JH, Duong-Polk XT, Taylor JM et al.: Transgenic expression of cholesterol-7-a-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler. Thromb. Vasc. Biol. 22, 121–126 (2002).
  • Ratliff EP, Gutierrez A, Davis RA: Transgenic expression of CYP7A1 in LDL receptordeficient mice blocks diet-induced hypercholesterolemia. J. Lipid Res. 47, 1513–1520 (2006).
  • Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L: Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13, 298–309 (2007).
  • Lu TT, Makishima M, Repa JJ et al.: Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507–515 (2000).
  • FXR activation is shown to strongly reduce atherosclerosis formation in multiple mouse models.
  • Comprehensive study of how various bile acids alter cholesterol absorption in mice.
  • Goodwin B, Jones SA, Price RR et al.: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517–526 (2000).
  • One of the initial papers describing the importance of the FXR/SHP pathway in bile acid metabolism.
  • Inagaki T, Choi M, Moschetta A et al.: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217–225 (2005).
  • Jung D, Inagaki T, Dawson PA et al.: FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 48, 2693–2700 (2007).
  • Kim I, Ahn SH, Inagaki T et al.: Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664–2672 (2007).
  • Wang DQ, Tazuma S, Cohen DE, Carey MC: Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstonesusceptible mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G494–G502 (2003).
  • Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ: Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J. Lipid Res. 50, 1090–1100 (2009).
  • An overview of farnesoid X receptor (FXR) in regard to liver biology.
  • Kok T, Hulzebos CV, Wolters H et al.: Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice. J. Biol. Chem. 278, 41930–41937 (2003).
  • Lambert G, Amar MJA, Guo G et al.: The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563–2570 (2003).
  • Hubbert ML, Zhang Y, Lee FY, Edwards PA: Regulation of hepatic Insig-2 by the farnesoid X receptor. Mol. Endocrinol. 21, 1359–1369 (2007).
  • Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ: Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors a and b. J. Biol. Chem. 277, 18793–18800 (2002).
  • Costet P, Krempf M, Cariou B: PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem. Sci. 33, 426–434 (2008).
  • Langhia C, Le Maya C, Kourimatea S et al.: Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 582, 949–955 (2008).
  • Watanabe M, Houten SM, Wang L et al.: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408–1418 (2004).
  • Wang L, Lee YK, Bundman D et al.: Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell 2, 721–731 (2002).
  • One of the initial papers describing the importance of the FXR/small heterodimer partner (SHP) pathway in bile acid metabolism.
  • Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I: Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J. 24, 2624–2633 (2005).
  • Lai L, Harnish DC, Evans MJ: Estrogen receptor a regulates expression of the orphan receptor small heterodimer partner. J. Biol. Chem. 278, 36418–36429 (2003).
  • Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI: Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290, E716–E722 (2006).
  • Kast HR, Nguyen CM, Sinal CJ et al.: Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15, 1720–1728 (2001).
  • Spotlights the control of ApoC-II expression by FXR and its role in regulation of plasma TG levels.
  • Claudel T, Inoue Y, Barbier O et al.: Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125, 544–555 (2003).
  • Brown RJ, Rader DJ: Lipases as modulators of atherosclerosis in murine models. Curr. Drug Targets 8, 1307–1319 (2007).
  • Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R: Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279, 45685–45692 (2004).
  • Anisfeld AM, Kast-Woelbern HR, Meyer ME et al.: Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J. Biol. Chem. 278, 20420–20428 (2003).
  • Sirvent A, Claudel T, Martin G et al.: The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 566, 173–177 (2004).
  • Pineda Torra I, Claudel T, Duval C et al.: Bile acids induce the expression of the human peroxisome proliferator-activated receptor a gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17, 259–272 (2003).
  • Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ: Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731–744 (2000).
  • Evans MJ, Mahaney PE, Borges-Marcucci L et al.: A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G543–G552 (2009).
  • Zhang Y, Wang X, Vales C et al.: FXR deficiency causes reduced atherosclerosis in LDLR-/- mice. Arterioscler. Thromb. Vasc. Biol. 26, 2316–2321 (2006).
  • Hanniman EA, Lambert G, McCarthy TC, Sinal CJ: Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46, 2595–2604 (2005).
  • Guo GL, Santamarina-Fojo S, Akiyama TE et al.: Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 1761, 1401–1409 (2006).
  • Hu T, Chouinar M, Cox AL et al.: Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J. Biol. Chem. 281, 39831–39838 (2006).
  • Bishop-Bailey D, Walsh DT, Warner TD: Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl Acad. Sci. USA 101, 3668–3673 (2004).
  • Pellicciari R, Fiorucci S, Camaioni E et al.: 6a-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569–3572 (2002).
  • Maloney PR, Parks DJ, Haffner CD et al.: Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 43, 2971–2974 (2000).
  • Flatt B, Martin R, Wang TL et al.: Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor. J. Med. Chem. 52, 904–907 (2009).
  • Mencarelli A, Renga B, Distrutti E, Fiorucci S: Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296, H272–H281 (2009).
  • Another paper using a distinct FXR ligand to demonstrate that FXR activation reduces atherosclerosis in the mouse.
  • Zhang Y, Lee FY, Barrera G et al.: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103, 1006–1011 (2006).
  • Authoritative review of the details of FXR and its biology.
  • Demonstrates a potential utility for FXR in both dyslipidemia and diabetes.
  • Claudel T, Sturm E, Duez H et al.: Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109, 961–971 (2002).
  • Sanyal S, Bavner A, Haroniti A et al.: Involvement of repressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc. Natl. Acad. Sci. USA 40, 15665–15670 (2007).
  • Goodwin B, Watson MA, Kim H et al.: Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-a. Mol. Endocrinol. 17, 386–394 (2003).
  • Quinet EM, Basso MD, Halpern AR et al.: LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J. Lipid Res. DOI: 10.11984/jlr.M900037-JLR200 (2009) (Epub ahead of print).
  • Downes M, Verdecia MA, Roecker A et al.: A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11, 1079–1092 (2003).
  • Wang S, Lai K, Moy FJ, Bhat A, Hartman HB, Evans MJ: The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology 147, 4025–4033 (2006).
  • Xing Y, Saner-Amigh K, Nakamura Y et al.: The farnesoid X receptor regulates transcription of 3b-hydroxysteroid dehydrogenase type 2 in human adrenal cells. Mol. Cell. Endocrinol. 299, 153–162 (2009).
  • Henry RR, Mudaliar S, Morrow L et al.: 13-LB. Farnesoid-X Receptor Agonists: A New Therapeutic Class for Diabetes and Fatty Liver Disease? The First FXR Therapeutic Study in Diabetes. Presented at: American Diabetes Association’s 69th Annual Scientific Sessions. New Orleans, LA, USA, 5–9 June (2009).
  • Szapary PO, Wolfe ML, Bloedon LT et al.: Guggulipid for the treatment of hypercholesterolemia. A randomized controlled trial. JAMA 290, 765–772 (2003).
  • Burris TP, Montros C, Houck KA et al.: The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol. 67, 948–954 (2005).
  • Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B: Role of bile acids and bile acid receptors in metabolic regulations. Physiol. Rev. 89, 147–191 (2009).
  • Initial description of FXR-deficient mice.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.